Cleveland State University

EngagedScholarship@CSU
Biological, Geological, and Environmental
Faculty Publications

Biological, Geological, and Environmental
Sciences Department

1-1-2016

Orally Active and Selective Tubulin Inhibitors As AntiTrypanosome Agents
Vishal Nanavaty
Cleveland State University

Rati Lama
Cleveland State University

Ranjodh Sandhu
Cleveland State University

Bo Zhong
Cleveland State University

Daniel Kulman
Cleveland State University

See next page for additional authors
Follow this and additional works at: https://engagedscholarship.csuohio.edu/scibges_facpub
Part of the Biology Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Nanavaty, Vishal; Lama, Rati; Sandhu, Ranjodh; Zhong, Bo; Kulman, Daniel; Bobba, Viharika; Zhao, Anran;
Li, Bibo; and Su, Bin, "Orally Active and Selective Tubulin Inhibitors As Anti-Trypanosome Agents" (2016).
Biological, Geological, and Environmental Faculty Publications. 234.
https://engagedscholarship.csuohio.edu/scibges_facpub/234

This Article is brought to you for free and open access by the Biological, Geological, and Environmental Sciences
Department at EngagedScholarship@CSU. It has been accepted for inclusion in Biological, Geological, and
Environmental Faculty Publications by an authorized administrator of EngagedScholarship@CSU. For more
information, please contact library.es@csuohio.edu.

Authors
Vishal Nanavaty, Rati Lama, Ranjodh Sandhu, Bo Zhong, Daniel Kulman, Viharika Bobba, Anran Zhao, Bibo
Li, and Bin Su

This article is available at EngagedScholarship@CSU: https://engagedscholarship.csuohio.edu/scibges_facpub/234

RESEARCH ARTICLE
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There is an urgent need to develop a safe, effective, orally active, and inexpensive therapy
for African trypanosomiasis due to the drawbacks of current drugs. Selective tubulin inhibitors have the potential to be promising drug candidates for the treatment of this disease,
which is based on the tubulin protein structural difference between mammalian and trypanosome cells. We propose to identify novel tubulin inhibitors from a compound library developed based on the lead compounds that selectively target trypanosomiasis.

Methods
We used Trypanosoma brucei brucei as the parasite model, and human normal kidney cells
and mouse microphage cells as the host model. Growth rates of both trypanosomes and
mammalian cells were determined as a means to screen compounds that selectively inhibit
the proliferation of parasites. Furthermore, we examined the cell cycle profile of the parasite
and compared tubulin polymerization dynamics before and after the treatment using identified compounds. Last, in vivo anti-parasite activities of these compounds were determined
in T. brucei-infected mice.

Results
Three compounds were selected that are 100 fold more effective against the growth of T.
brucei cells than mammalian cells. These compounds caused cell cycle progression
defects in T. brucei cells. Western analyses indicated that these compounds decreased
tubulin polymerization in T. brucei cells. The in vivo investigation revealed that these compounds, when admitted orally, inhibited T. brucei cell proliferation in mouse blood. However,
they were not potent enough to clear up the infection completely.
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Conclusions
These compounds are promising lead compounds as orally active agents for drug development of anti-trypanosome agents. A more detail structure activity relationship (SAR) was
summarized that will be used to guide future lead optimization to improve the selectivity and
potency of the current compounds.

Introduction
Human African trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic
disease in sub-Saharan Africa with very limited medical resources[1–3]. Trypanosoma brucei
gambiense (T. b. gambiense) and Trypanosoma brucei rhodesiense (T. b. rhodesiense) are the etiological parasites of sleeping sickness in humans. In West and Central Africa, T. b. gambiense
is the major parasite that causes the disease, while in sub-Saharan Africa, T. b. rhodesiense predominates. These trypanosome subspecies are responsible for the West and East African forms
of the disease, respectively[2]. A third closely related subspecies Trypanosoma brucei brucei
(T. b. brucei), cannot survive in the human host due to the human serum lytic factor, but is
responsible for many cases of nagana in cattle. It significantly impairs the agricultural growth
in Africa[4,5]. As T. b. brucei shares many features with T. b. gambiense and T. b. rhodesiense
(such as antigenic variation), it is often used as a model for human infections in laboratory and
animal studies.
These parasites live and grow extracellularly in the blood and tissue fluids of humans or cattle, and are transmitted among hosts by tsetse flies (Glossina spp.). At the beginning of the
infection, trypanosomes proliferate in the bloodstream and lymphatic system. Eventually, these
parasites cross the blood-brain barrier and enter the central nervous system. At this stage,
patients show a variety of neurological symptoms and often exhibit an alteration of the circadian sleep/wake pattern, which is why the disease is called “sleeping sickness”. Without effective treatment, the disease will result in coma and ultimately death. If the patient does not
receive treatment before parasites invade the central nervous system, neurological damages
caused by parasites are irreversible even after later treatment[3,6]. Therefore, an effective and
early treatment is critical.
The current treatment of human trypanosomiasis relies on only four drugs including Suramin, Pentamidine, Melarsoprol and Eflornithine[5]. The main drawbacks of these drugs are: 1)
they are toxic to the hosts, which is mainly due to their poor selectivity to parasites than host
cells; 2) they can be only administered via intramuscular or intravenous injections; 3) they
have very narrow anti-trypanosomiasis spectrum; and 4) their use depends on costly medical
resources. Overall, these drugs are not successful in the treatment of the disease, and there is a
general lack of effective, inexpensive chemotherapeutic agents for the treatment of human African trypanosomiasis. Therefore, improved chemotherapeutic agents with better selectivity to
the trypanosomes are needed to effectively battle this disease[5–7].
Tubulin-containing structures are important for many important cellular functions such
cell division, intracellular transport, development and maintenance of cell shape, cell motility,
and distribution of molecules on cell surface[8]. Tubulin is a very attractive target in the
anti-cancer drug discovery field, and several successful tubulin binders are the first line chemotherapeutic agents in clinic[9]. Tubulin also plays an essential role during trypanosome cell
division. The fast population doubling rate of trypanosomes makes them highly dependent on
tubulin polymerization/depolymerization[10]. More importantly, tubulin is very critical for
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trypanosome locomotion, which is an essential function for trypanosomes to survive. Tubulin
inhibitors will not only block the T. brucei cell division but will also affect the locomotion function of flagellum and lead to cell death[11]. The flagellar pocket is known to be an important
structure in uptake and internalization of molecules for trypanosomes[12]. Such uptake could
enhance the binding of tubulin inhibitors to intracellular tubulin, particularly in the flagella
pocket. Therefore, tubulin inhibitors could be effective agents to suppress flagellar locomotion
function[11]. These factors indicate that there are advantages of tubulin inhibitors for the treatment of trypanosomiasis.
Tubulin is a highly conserved protein. However, differences in susceptibility to antimitotic
agents are known to exist between tubulins from different organisms, indicating that differences of tubulin structures exist among different species[13]. Based on the differences of tubulin in T. brucei and mammalian cells, it is highly expected that selective tubulin inhibitors
could be developed. We have developed a class of tubulin inhibitors as anti-cancer agents
[14,15]. These compounds share the same core scaffold, and bind to colchicine-binding
domain on tubulin[14]. Based on differences of the binding pocket between mammalian and
T. brucei tubulins, we examined the growth of T. brucei and mammalian cells treated with our
compounds as a screening test[16]. Some compounds exhibited very specific inhibitory effect
on T. brucei growth, with selectivity index (IC50 inhibiting human cell growth/IC50 inhibiting
T. brucei cell growth) being 5 or more. More importantly, the pharmacophore of these compounds enhancing the mammalian cell growth inhibition was different to the pharmacophore
promoting the T. brucei cell growth inhibition. In the current study, we screened a compound
library including 79 derivatives developed based on previous lead compounds. More selective
tubulin inhibitors were identified and they exhibited potent tubulin polymerization inhibition
in T. brucei cells and also caused defective cytokinesis. Furthermore, selected candidates
showed in vivo activities to inhibit T. brucei replication in infected mice when administered
orally.

Materials and Methods
Reagents and animals
Sulfonamide tubulin inhibitors were synthesized in our laboratory and the procedures were
described in previous studies[17,18]. All the structures of the compounds are listed in Fig 1.
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium (MTS) reagents were from Promega life science (Madison, WI). 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) and sesame oil were
from Sigma-Aldrich (Milwaukie, WI). 3 month old female CD1 mice were purchased from
Charles River laboratory.

Cell culture
HEK293 kidney cells, mouse macrophage RAW267.4 cells were obtained from ATCC (Rockville, MD) and maintained in RPMI1640 medium supplemented with 10% fetal bovine serum
(FBS), 2 mmol/L L-Glutamine, 1 mmol/L sodium pyruvate, and 100 U/mL penicillin-streptomycin. FBS was heat inactivated for 30 min at 56°C. Mammalian cells were grown at 37°C, in a
Heraeus water-jacketed incubator with 5% CO2. T. b. brucei Lister 427 cells were cultured in
HMI-9 medium [19] with 10% FBS at 37°C in a Heraeus water-jacketed incubator with 7.5%
CO2.
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Fig 1. Structures of the compounds.
doi:10.1371/journal.pone.0146289.g001

Mammalian cell viability analysis
The MTT assay was used to examine the effect of tubulin inhibitors on HEK293 and
RAW267.4 cell growth with quadruplication. Cells were grown in RPMI1640 medium in
96-well flat-bottomed plates for 24 hrs and were exposed to various concentrations of test
compounds dissolved in DMSO (final concentration 0.1%) in medium for 48 hrs. Controls
received DMSO at a concentration the same as that in drug-treated cells. Cells were incubated
in 200 μl of 0.5 mg/ml of MTT reagent diluted in fresh media at 37°C for 2 hrs. Supernatants
were removed from the wells, and the reduced MTT dye was solubilized in 200 μl/well DMSO.
Absorbance at 570 nm was determined on a SpectraMax Plus384 spectrophotometer (Molecular Devices). Data obtained with quadruplication were normalized and fitted to a dose–
response curve using GraphPad Prism v.5 (GraphPad), and standard deviations were used.
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T. brucei cell viability analysis
The MTS assay was used to examine the effect of tubulin inhibitors on T. b. brucei cell viability
[16]. 5000 cells of T. brucei were seeded in 96 well plates and treated with 0.1% DMSO and
tested agents at various concentrations for 48 hrs at 37°C. Subsequently, 20 μL of MTS (5%
PMS) from the CellTiter Cell Proliferation Assay (Promega) was added to 200 μL of T. b. brucei
culture in each well and incubated at 37°C for an 3 hrs. Soluble formazan, produced by viable
cells due to reduction of MTS, was measured at 490 nm with a SpectraMax Plus384 spectrophotometer (Molecular Devices). Data obtained with quadruplication were normalized and fitted to a dose–response curve using GraphPad Prism v.5 (GraphPad), and standard deviations
were used.

Fluorescence Activated Cell Sorting (FACS) analysis
T. brucei cells were incubated with 0.5% DMSO (as a control), compound 79 (500 nM), compound 11 (500 nM), and 12 (500 nM) for 7 hrs. Subsequently, 0.1 million cells were harvested
at 1500 rpm for 10 mins at 4°C, washed twice with 1 x PBS/2 mM EDTA, and resuspended in
200 μl of 1 x PBS/2 mM EDTA per 0.1 million cells in 15 ml conical tubes. Cells were then
fixed by adding 2 mL of icy-cold 70% EtOH during vortexing followed by incubating at 4°C for
a minimum of 16 hrs. Cell pellets were collected by centrifugation at 1,000 rpm for 5 mins at
4°C and stained with 0.5 mL of staining solution (950 μl of 1xPBS/2mM EDTA, 20 μl of
RNAse A (10 mg/ml), 50 μl of propidium iodide (1 mg/ml)) at 37°C for 30 mins and filtered
for the Fluorescence Activated Cell Sorting (FACS) analysis. FACS was done on FACS Aria II
(BD Biosciences) and data from three independent experiments were analyzed using the
Flowjo software.

T. brucei cell lysate preparation and Western blotting
T. brucei cells were incubated with 0.5% DMSO, compound 79 (500 nM), compound 11
(500 nM), and 12 (500 nM) for 24 hrs. Cell pellets were harvested by centrifugation 1,500 rpm
for 10 mins at 4°C, washed twice with 1X TDB buffer (5 mM KCl, 80 mM NaCl, 1 mM MgSO4,
20 mM Na2HPO4, 2 mM NaH2PO4, 20 mM glucose, pH 7.4) with one complete protease
inhibitor tablet (Roche), and lysed with 300 μl of lysis buffer (80 mM Pipes, pH 6.8, 1 mM
EGTA, 1 mM MgCl2, 0.2% Triton X-100, 10% glycerol and one complete protease inhibitor
tablet (Roche)) at 30°C for 5 mins. The cell lysate was centrifuged at 2,000 rpm for 10 mins at
4°C, and the supernatant was transferred into a fresh Eppendorf tube. Pellets were re-suspended in lysis buffer and sonicated. 50 μl of 2 x SDS buffer was added to equal volume of cell
lysate and re-suspended pellet fraction, which were boiled at 95°C for 5 mins. Protein lysates
from equal number of cells were separated on 10% polyacrylamide gels by electrophoresis. Proteins were transferred onto nylon hyblot CL membranes. Tubulin antibody (TAT-1, a gift from
Dr. K. Gull) was used in the following western analysis. The experiments were repeated three
times and the representative bands are listed.

In vivo testing
The animal study was approved by Cleveland State University animal care and use committee
and adheres to the Guide for the Care and Use of Laboratory Animals, 8th edition (NIH). 3
month old female mice (Charles River) were randomly divided to three groups (4 mice per
group) and infected with 100,000 T. brucei cells per mouse via intraperitoneal injection. On the
second day, mice were started to be treated daily via oral gavage with individual compounds
(compound 79 at a dose of 400 mg/kg and compound 12 at a dose of 200 mg/kg) using the
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sesame oil formulation (200uL per mouse as administration) for four days. The negative control group received sesame oil and vehicle DMSO. We also used Pentamidine (20mg/kg ip
injection once) as a positive control and it totally cleared up the infection by the end of the
treatment with only one injection on the second day after infection. Due to the different
administration routes, the results of Pentamidine were not listed. Start on day 3, 5 μl of tail
blood was collected daily for T. brucei cell counting. More specifically, the T. brucei cells in the
blood was diluted 200 times with TDB buffer and counted with a hemocytometer. The parasitemia level was evaluated by the T. brucei cell number in the blood based on the counting. Mice
were euthanized with isoflurane overdose when parasitemia reached more than 200 million
cells/mL in blood. Mice weight was examined before and after treatment.

Results and Discussion
Compound screening identified three candidates as the most potent and
selective ones to inhibit T. brucei growth
We examined inhibitory activities of tubulin inhibitors synthesized in our laboratory using a
cell proliferation assay. T. b. brucei Lister 427 cells were used as the parasite model, and human
normal kidney cells HEK293 and mouse macrophage RAW267.4 cells were used as the mammalian cell control.
Results of cell growth inhibition are shown in Table 1.
The selective index is calculated by dividing the IC50s of the mammalian cell growth inhibition by the IC50s of the T. brucei cell growth inhibition.
For the four moieties (R1 –R4) of the compound scaffold, various functional groups were
introduced to enhance the anti-trypanosome activity and decrease anti-mammalian cell activity (Fig 2).
For R1 domain, some analogs were designed with alkyl and aryl groups as the substituents.
To increase the structural variability, we also set electron-withdrawing and donating group
substituted aryl group as R1 moiety. Based on IC50s of the mammalian cell growth inhibition,
aryl groups are preferred to target mammalian cells. Particularly, the 2, 5-dimethylbenzyl moiety and 2, 5-dimethoxybenzyl group dramatically increased the inhibition of mammalian cell
proliferation. Several derivatives (compounds 13–18, 38–43) inhibited the proliferation of
HEK293 and RAW267.4 cells with IC50 values at subnanomolar level (Table 1), which is also
consistent to our previous anti-cancer investigation of these compounds[17,18]. Obviously,
methoxy group is not a good substituent on this scaffold for anti-trypanosome agents, because
it is expected to increase the toxicity to host cells. The Alkyl group such as hexyl at the R1 moiety (compounds 7–12) significantly decreased the inhibition to mammalian cell growth, and it
has the similar activity against T. brucei cell proliferation as the aryl substituted analogs. Electron-withdrawing group substituted aryl moiety (compounds 19–24) decreased the anti-mammalian cell activity compared to the electron-donating group (compounds 13–18), but did not
affect the anti-trypanosome activity significantly. Therefore, it makes sense to synthesize more
alkyl substituent groups and electron-withdrawing group bonded aryl groups at R1 moiety in
future optimization.
For R2 moiety, it seems that a middle sized alkyl group benefits both inhibitions to mammalian and T. brucei cell growth. Compounds 37–42, 67–70 exhibited lower potency than their
N-methyl derivatives 13–18 and 71–74, respectively. This result indicates that hydrogen is the
least preferred substituent at R2. On the other hand, methyl group promoted the activity
against all mammalian and T. brucei cells. More bulky groups are not preferred either, because
ethyl and propyl groups decreased the activity in all tests compared to corresponding methyl
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Table 1. Comparison of the growth inhibitory effects of the tubulin inhibitors on mammalian and T. brucei cells (IC50 ± standard deviations are
used to indicate the potency of the compounds).
Comp

IC50 against T.brucei
cell growth (μM)

IC50 against macrophage
RAW267.4 cell growth (μM)IC50

IC50 of macrophage cells
/IC50 of T. brucei

IC50 against HEK293
cell growth (μM)

1

0.77 ± 0.29

2.80 ± 1.81

3.6

1.53 ± 0.65

2

2

4.08 ± 1.96

1.09 ± 0.75

0.3

0.39 ± 0.15

0.1

3

4.41 ± 2.41

2.60 ± 1.74

0.59

1.74 ± 0.77

0.4

4

0.31 ± 0.15

0.52 ± 0.34

1.7

0.31 ± 0.11

1

5

1.64 ± 0.55

1.26 ± 0.63

0.8

21.60 ± 12.10

13.2

6

7.98 ± 3.39

3.31 ± 2.09

0.4

15.80 ± 7.79

2

7

0.99 ± 0.28

121.20 ±58.08

122.4

74.90 ± 33.20

75.7

8

1.09 ± 0.43

10.10 ± 4.65

9.3

41.40 ± 16.40

38

9

3.39 ± 1.22

65.90 ± 25.30

19.4

50.90 ± 23.10

15

10

1.68 ± 0.84

11.20 ± 7.01

6.7

8.53 ± 2.86

5.1

IC50 of HEK293 cells
/IC50 of T. brucei

11

1.16 ± 0.62

>200.0

>172.4

195.0 ± 146.0

168.1

12

0.82 ± 0.41

>200.0

>243.9

192.0 ± 129.0

234.1

13

1.25 ± 0.44

0.012 ± 0.008

0.01

0.025± 0.012

0.02

14

7.17 ± 3.42

0.001± 0.0005

0.0001

0.001±0.0004

0.0001

15

3.19 ± 1.42

0.067 ± 0.051

0.02

0.031 ± 0.019

0.01

16

0.79 ± 0.32

0.007± 0.0004

0.01

0.004 ± 0.001

0.05

17

2.49 ± 1.54

0.009± 0.005

0.004

0.005 ± 0.002

0.002

18

10.0 ± 4.89

0.004 ± 0.002

0.0004

0.008 ± 0.003

0.0008

19

2.37 ± 0.96

3.15 ± 1.97

1.3

11.20 ± 4.87

4.7

20

3.46 ± 1.85

1.21 ± 0.58

0.3

2.73 ± 1.34

0.8

21

6.35 ± 2.30

1.90 ± 0.90

0.3

3.48 ± 1.56

0.5

22

0.80 ± 0.24

1.94 ± 1.12

2.4

0.80 ± 0.37

1

23

2.15 ± 0.61

4.98 ± 2.61

2.3

0.86 ± 0.26

0.4

24

2.40 ± 0.96

4.67 ± 2.33

1.9

8.99 ± 3.54

3.7

25

0.47 ± 0.17

8.98 ± 4.65

19.1

6.36 ± 3.99

13.5

26

1.29 ± 0.51

3.79 ± 1.83

2.9

5.85 ± 3.97

4.5

27

3.91 ± 2.27

12.70 ± 6.89

3.2

1.63 ± 0.80

0.4

28

0.73 ± 0.38

2.57 ± 1.53

3.5

2.81 ± 1.02

3.8

29

1.07 ± 0.44

30.76 ± 13.67

28.7

27.90 ± 6.45

26.1

30

2.25 ± 0.77

9.91 ± 4.82

4.4

5.88 ± 2.53

2.6

31

0.37 ± 0.15

0.52 ± 0.32

1.4

0.41 ± 0.09

1.1

32

0.89 ± 0.41

0.17 ± 0.08

0.2

0.15 ± 0.05

0.2

33

2.09 ± 0.98

0.48 ± 0.27

0.2

0.79 ± 0.26

0.4

34

0.34 ± 0.16

0.18 ± 0.09

0.5

0.14 ± 0.06

0.4

35

0.50 ± 0.11

1.25 ± 0.83

2.5

0.76 ± 0.26

1.5

36

1.12 ± 0.39

0.42 ± 0.23

0.4

0.26 ± 0.09

0.5

37

8.54 ± 4.26

0.051 ± 0.030

0.006

0.061± 0.026

0.007

38

72.90± 2.20

0.010 ± 0.005

0.0001

0.011 ± 0.007

0.0002

39

9.13 ± 4.39

0.039 ± 0.019

0.004

0.028 ± 0.013

0.003

40

14.0 ± 4.88

0.018 ± 0.010

0.001

0.009 ± 0.004

0.0006

41

190.90±138.50

0.021±0.011

0.0001

0.013 ± 0.006

0.00007

42

96.20 ± 56.90

0.016±0.008

0.0002

0.015 ± 0.006

0.0002

43

2.69 ± 0.89

0.016±0.011

0.006

0.014 ± 0.005

0.005

44

2.04 ± 1.02

0.043±0.017

0.02

0.005 ± 0.002

0.002

45

0.92 ± 0.23

0.055±0.027

0.06

0.006 ± 0.003

0.007
(Continued)
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Table 1. (Continued)
IC50 against T.brucei
cell growth (μM)

IC50 against macrophage
RAW267.4 cell growth (μM)IC50

46

0.32 ± 0.10

47

22.60 ± 9.85

48

Comp

IC50 of macrophage cells
/IC50 of T. brucei

IC50 against HEK293
cell growth (μM)

0.007±0.003

0.02

0.005 ± 0.002

0.02

0.11 ± 0.05

0.005

0.12 ± 0.05

0.005

10.60 ± 4.89

0.23 ± 0.07

0.02

0.20 ± 0.06

0.02

49

1.48 ± 0.59

0.072±0.033

0.05

0.41 ± 0.19

0.3

50

1.31 ± 0.52

0.065±0.037

0.05

0.070 ± 0.020

0.05

51

2.29 ± 1.11

0.20 ± 0.090

0.09

1.31 ± 0.35

0.6

52

2.53 ± 1.37

1.99 ± 1.03

0.8

1.23 ± 0.42

0.5

53

0.56 ± 0.21

0.83 ± 0.51

1.5

0.69 ± 0.29

1.8

54

0.36 ± 0.13

0.18 ± 0.09

0.5

0.06 ± 0.02

0.2

55

9.43 ± 4.42

2.25 ± 0.87

0.2

1.96 ± 0.99

0.2

56

11.90 ± 5.84

10.35 ± 3.82

0.9

6.61 ± 2.02

0.6

57

2.13 ± 0.96

13.10 ± 5.51

6.2

15.90 ± 8.43

7.5

58

1.73 ± 0.68

1.74 ± 0.61

1

1.26 ± 0.73

0.7

59

1.04 ± 0.48

0.015±0.009

0.01

0.019 ± 0.009

0.01

IC50 of HEK293 cells
/IC50 of T. brucei

60

0.20 ± 0.08

0.010±0.004

0.05

0.010 ± 0.005

0.05

61

1.85 ± 1.12

0.39 ± 0.21

0.2

0.17 ± 0.07

0.1

62

1.41 ± 0.75

0.29 ± 0.16

0.2

0.18 ± 0.08

0.1

63

2.33 ± 0.96

0.064±0.030

0.03

0.18 ± 0.09

0.3

64

0.54 ± 0.16

0.06± 0.03

0.1

0.06 ± 0.02

0.1

65

4.42 ± 1.31

1.25 ± 0.50

0.3

2.25 ± 1.02

0.5

66

2.12 ± 0.76

0.56 ± 0.21

0.3

0.75 ± 0.40

0.4

67

43.50 ± 23.50

0.044±0.019

0.001

0.027 ± 0.012

0.0006

68

45.90 ± 26.50

0.076±0.037

0.002

0.065 ± 0.028

0.001

69

1.34 ± 0.68

0.085±0.047

0.06

0.049 ± 0.022

0.04

70

1.19 ± 0.53

0.037±0.017

0.03

0.036 ± 0.011

0.03

71

31.50 ± 15.60

0.007±0.003

0.0002

0.004 ± 0.002

0.0001

72

3.02 ± 2.30

0.057±0.030

0.02

0.049 ± 0.021

0.02

73

1.88 ± 1.12

0.044±0.023

0.02

0.012 ± 0.004

0.006

74

0.41 ± 0.19

0.006±0.002

0.01

0.004 ± 0.002

0.01

75

3.45 ± 1.25

0.21 ± 0.12

0.06

0.11 ± 0.04

0.03

76

1.95 ± 1.16

0.23 ± 0.12

0.1

0.11 ± 0.05

0.06

77

2.43 ± 1.47

0.010±0.004

0.004

0.020± 0.012

0.008

78

2.01 ± 1.13

0.95 ± 0.66

0.5

0.73 ± 0.36

0.4

79

0.68 ± 0.13

69.55±23.36

102.3

92.36 ± 43.25

135.8

doi:10.1371/journal.pone.0146289.t001

analogs. Therefore, it is difficult to increase the selectivity of the compounds to T. brucei cells
by modifying R2 moiety.
Fortunately, R3 moiety is a good domain to increase the selectivity of the compounds.
Replacing methyl sulfonamide group in these compounds with trifluoromethyl sulfonamide
group (compounds 25–36) significantly impaired their activity against mammalian cell
proliferation, suggesting that the trifluoromethyl sulfonamide group was well tolerated by the
mammalian cells. Unexpectedly, this modification increased the anti-trypanosome activity
simultaneously, indicated by IC50s of compounds 13–18 verse 31–36. All trifluoromethyl analogs showed better activity against T. brucei cell growth than their corresponding methyl analogs. In terms of bulkiness factor, methyl and ethyl groups showed similar activities in both
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Fig 2. SAR results of the anti-mammalian cell growth activity and anti-T. brucei growth activity of the sulfonamide tubulin inhibitors.
doi:10.1371/journal.pone.0146289.g002

parasitic and mammalian cells, and propyl group decreased both activities. Arylsulfonamides
and alkyl/arylsulfonamides (59–66) all showed potent activity against T. brucei cells with low
micromole IC50s. However, the greatly reduced water solubility of these compounds limits further optimization to any other aryl substituent at R3 domain. Overall, to increase the activity
and selectivity of the compound for the inhibition of T. brucei cell growth, trifluoromethyl is
the best fit for R3, and it will be included in the future optimization.
At R4 moiety, methoxy groups impaired the anti-trypanosome activity but increased the
activity against mammalian cells, which is represented by compounds 14 and 38. Halogen
atom iodine improved the activity to against both T. brucei and mammalian cells, which is indicated by compounds 16, 22, 28, and 46. We haven’t identified any group at R4 domain that
would only increase the anti-trypanosome activity in the current investigation. However, our
previous study suggested that electron-withdrawing group such as trifluoromethyl might
increase the selectivity to inhibit T. brucei cell growth[16]. In the future, further optimization
will be mainly focused on R1 and R4 moieties, R2 will be the methyl group and R3 will be the
trifluoromethyl group. Based on the selective index (we used 100 as the cutoff for selection), we
selected compounds 11, 12 and 79 for the following anti-trypanosomal mechanism investigation and in vivo activity determination.

Three compounds inhibit tubulin polymerization and affect T. brucei cell
cycle progression
Our current compounds were developed based on our previous results, and the lead compounds were speculated to be selective tubulin inhibitors for T. brucei cells[16]. Therefore, we
examined if the selected new drug candidates could affect cell cycle progression in T. brucei
cells. Three compounds (11, 12, and 79) at 0.5 μM significantly decreased cell proliferation
after 7 hrs treatment and led to cell death at later stage (Fig 3).
FACS analysis of cells treated for 7 hrs showed that there were significantly more G2/M
phase cells in the population, although this increase was mild. This suggests that cells may
spend a longer time during G2/M, which is consistent with the idea that mitosis progression is
delayed. We also observed significantly more cells carrying 4C and 8C DNA contents among
the cell population (Fig 3 and Table 2).
It is known that bloodstream form T. brucei cells have a cytokinesis checkpoint where cell
division is blocked but DNA replication can continue, leading to accumulation of 4C and 8C
cells[20]. Our FACS analysis gave the same cell cycle profile as cells in cytokinesis checkpoint,
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Fig 3. Tubulin inhibitors cause defective cell cycle progression and inhibit tubulin polymerization.
FACS, Western blot and cell growth are all from three independent experiments. (A) T. brucei cells were
treated with 0.5% DMSO, compound 79 (500 nM), compound 11 (500 nM), and 12 (500 nM) for 24 hrs, the
soluble tubulin and non-soluble microtubules are examined with western blot. The level of soluble tubulin
(non-polymerized tubulin) is significantly increased. (B) T. brucei cells were treated with 0.5% DMSO,
compound 79 (500 nM), compound 11 (500 nM), and 12 (500 nM) for 7 hrs. The cells were harvested and
stained with propidium iodide, then examined with FACS analysis. Compounds treatment causes defective
cell cycle progression. (C) Compounds treatment significantly decreases cell division. T. brucei cells were
treated with 0.5% DMSO, compound 79 (500 nM), compound 11 (500 nM), and 12 (500 nM) for 14 hrs. At
7hrs and 14hrs, cells were collected and the cell number was counted with a hemocytometer.
doi:10.1371/journal.pone.0146289.g003

indicating that treating T. brucei cells with the tubulin blocker candidates caused cytokinesis
defects[20]. After 14 hrs treatment, cell death was significantly increased (Fig 3C), which prevented us from performing the FACS analysis. The significant cell death also indicates that the
compounds might interfere with other cell machinery to impact cell viability as well.
Our results suggest that the compounds mainly interfered with the microtubule dynamics.
To test this hypothesis, we determined the amount of the polymerized and the un-polymerized
tubulin after treating T. brucei cells with the same compounds. We found that all three compounds increased the amount of soluble tubulin (Fig 3A), indicating that after the treatment,
the soluble tubulin dimers were not efficiently converted to the insoluble tubulin polymers.
Therefore, our compounds likely inhibited tubulin polymerization in T. brucei cells, which in
turn caused a delay of G2/M progression and defective cytokinesis. They are a group of novel
T. brucei selective tubulin inhibitors.

Compounds 12 and 79 are orally active in in vivo studies using T. bruceiinfected mice
For drug discovery, the most critical part is the drug’s in vivo activity. We used an acute infection mouse model to investigate the in vivo activities of our identified compounds. The current
clinical drugs used to treat T. brucei infection are not orally active, and our focus is to develop
orally active drug candidates for the treatment. Therefore, the three drug candidates were
administered to the infected mice via oral gavage. When we prepared the drug formulation, the
low solubility of compound 11 limited its administration and was eliminated from the following assays. Compounds 12 and 79 both exhibited inhibitory activity to T. brucei proliferation
in mouse blood (Fig 4).
However, they cannot clear T. brucei infection completely, as T. brucei cell counts eventually
went up. There are several possible explanations for this observation. First, our compounds
may have low bio-availability, and very low percentage of drug can reach the portal vain after
oral gavage. Second, these compounds may have high first pass metabolism, and the original
drug lose its activity after being released from the liver. Third, these compounds may have high
serum protein binding affinity, and they cannot be effectively up taken by T. brucei cells.
Table 2. T. brucei cell distribution in different phases after the compound treatment. Compared to the control, all three compounds cause cell cycle
progression defects in T. brucei cells. FACS results from three independent experiments (mean ± standard deviation) are given.
(Treatment vs DMSO)
G1

S

G2/M

>4N

P value of G2/M

P value of >4N

DMSO

59.20±3.61

6.03±0.89

26.80±1.65

7.12±1.29

Comp 79(0.5μM)

49.63±1.89

5.40±0.57

33.27±0.21

Comp 11(0.5μM)

52.77±0.71

4.48±0.65

30.83±0.93

11.03±1.11

0.020

0.017

11.30±0.85

0.032

Comp 12(0.5μM)

50.10±1.51

5.48±0.07

33.67±1.10

0.013

10.24±0.66

0.006

0.034

doi:10.1371/journal.pone.0146289.t002
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Fig 4. In vivo testing of selective tubulin inhibitors. Mice were randomly divided to three groups (4 mice
per group) and infected with 100,000 T. brucei cells per mouse via intraperitoneal injection. Subsequently,
mice were treated daily via oral gavage with individual compounds (compound 79 at a dose of 400 mg/kg and
compound 12 at a dose of 200 mg/kg) using the sesame oil formulation. The control group received sesame
oil and vehicle DMSO. (A) T. brucei cell count of mouse tail blood after mice were treated with our
compounds. (B) Mouse weight change before and after the treatment.
doi:10.1371/journal.pone.0146289.g004

Nevertheless, the two selective tubulin inhibitors showed oral activities to inhibit T. brucei
growth in the animal model. Further optimization to increase the in vivo activities of these
compounds is needed in the future.

Conclusion
African trypanosomiasis is a threat to public health in sub-African regions. Without effective
vaccines and satisfactory drug treatments, the development of new drugs for the disease is
urgently needed. Our research leads to a unique molecular scaffold that selectively targets T.
brucei tubulin, and opens a new area on trypanosome-specific tubulin inhibitor development.
Based on the inhibitory effects of our compounds on T. brucei cell proliferation and mammalian cell growth, a SAR is summarized. The pharmacophore of the tubulin inhibitor promoting
the mammalian cell growth inhibition and the functional groups enhancing the parasite
growth inhibition are described in Fig 2. Furthermore, three highly selective tubulin inhibitors
were identified, and they interfered with tubulin polymerization in T. brucei cells, resulting in
defective cell cycle progression and increased soluble tubulin dimer levels in cell cytosol. In
addition, two drug candidates showed oral activities to block T. brucei cell proliferation in the
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mouse model, indicating that these compounds are good leads for further optimization. It is
therefore expected that more selective and potent tubulin inhibitors for trypanosome infections
could be developed based on this discovery.
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